- 专利标题： Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof
-
申请号： US17440527申请日： 2020-03-20
-
公开(公告)号： US12098175B2公开(公告)日： 2024-09-24
- 发明人: Andrea Cavalli , Jacopo Sgrignani , Mariagrazia Uguccioni
- 申请人： INSTITUTE FOR RESEARCH IN BIOMEDICINE
- 申请人地址： CH Bellinzona
- 专利权人： INSTITUTE FOR RESEARCH IN BIOMEDICINE
- 当前专利权人： INSTITUTE FOR RESEARCH IN BIOMEDICINE
- 当前专利权人地址： CH Bellinzona
- 代理机构： Harness Dickey & Pierce P.L.C.
- 优先权： WO TEP2019057125 2019.03.21
- 国际申请： PCT/EP2020/057892 2020.03.20
- 国际公布： WO2020/188110A 2020.09.24
- 进入国家日期： 2021-09-17
- 主分类号： C07K14/47
- IPC分类号： C07K14/47 ; A61K38/00 ; C07K7/06
摘要：
The present invention provides novel peptides binding to HMGB1 and inhibiting the interaction of HMGB1 and CX-CL12. The present invention also provides proteins, virus-like particles, nanoparticles and compositions comprising such peptides and nucleic acids encoding such peptides. In addition, methods for using the peptides are provided. In particular, the peptides are useful in the treatment of inflammation and immune-related diseases.
公开/授权文献
信息查询
